Clinical use of<unk>  was introduced in Europe in 1964, as anesthetic given intravenously but it was not widely used since it sometimes caused seizures; as of 2006, it was still authorized for this use in France and Italy but not widely used. The major use of<unk>  is in treating two of the symptoms of narcolepsy – cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Reviews of<unk>  concluded that it is well tolerated and associated with "significant reductions in cataplexy and daytime sleepiness," and that its effectiveness "in treating major, clinically relevant narcolepsy symptoms and sleep architecture abnormalities" has been established. However, because of the risks of abuse associated with this medication, it is available in the US only through a REMS program mandated by the FDA. The program requires that providers who prescribe it are certified to do so, that it is dispensed only from a central pharmacy that is certified to do so, and people to whom it is prescribed must be enrolled in a program for the drug and must document that they are using the drug safely. In more recent times, investigations of its use in dealing with alcohol withdrawal syndrome have begun. These started in Italy, where its use in treating alcohol addiction was also explored; the evidence for these uses is weak but growing and it has also been approved for use in Austria. There is insufficient evidence to make a definitive comparison with clomethiazole or benzodiazepine-based treatment approaches, though some data suggest it may be "better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months." In a 2014 review, Gillian Keating described<unk>  as a "useful option for the treatment of alcohol withdrawal syndrome and for the maintenance of abstinence in alcohol dependence." However, a 2018 review recognised the evidence for its efficacy but noted safety concerns and concluded that "studies are still limited and investigations including a larger number of patients are needed." Pregnant women should not take it, and women should not become pregnant while taking it. It is excreted in breast milk and should not be used by breast feeding mothers.
Sodium oxybate
Amine fluoride
Sodium thiosulfate 
Sodium fluoride
Potassium fluoride
Perchloryl fluoride
Silver diammine fluoride
Disufenton sodium